GIC Sub-Industry 'Biotechnology': 200+ results
| Symbol | Industry | Market Cap | Fund. Score | Div. Score | Tech. Score | P/E | Return 12m vs S&P 500 |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie |
Biotechnology
Biologics, Immunology, Oncology |
404B | 48.3% | 70.4% | 33.4% | 172 | 7.49% |
| AMGN Amgen |
Biotechnology
Biologics, Oncology, Osteoporosis |
176B | 82.2% | 71.4% | 54.7% | 25.3 | 6.14% |
| GILD Gilead Sciences |
Biotechnology
HIV, COVID-19, Hepatitis, Oncology |
151B | 81.9% | 60.1% | 63.8% | 18.8 | 14.5% |
| VRTX Vertex |
Biotechnology
Cystic Fibrosis, Gene Therapy |
116B | 86.4% | - | 39.9% | 32.0 | -6.38% |
| REGN Regeneron |
Biotechnology
Eye, Dermatology, Asthma, Cancer |
81.8B | 74.6% | 18.7% | 48.5% | 18.5 | -4.99% |
| ALNY Alnylam |
Biotechnology
ONPATTRO, AMVUTTRA, GIVLAARI |
52.9B | 61.8% | - | 32.1% | - | 38.4% |
| ARGX argenx |
Biotechnology
FcgRn-Blocker, MusK-Agonist |
52.3B | 71.1% | - | 33.2% | 36.0 | -0.68% |
| HLN Haleon |
Biotechnology
Toothpaste, Vitamins, Cold-Relief |
44.5B | 69.6% | 56.6% | 33.2% | 22.2 | -8.32% |
| INSM Insmed |
Biotechnology
Liposomal Antibiotic, DPP1 |
37.8B | 35.8% | - | 54.6% | - | 123% |
| ONC BeiGene |
Biotechnology
BTK Inhibitor, PD-1 Antibody, PARP |
35.5B | 64.6% | - | 45.9% | 628 | 58.1% |
| NTRA Natera |
Biotechnology
Panorama, Horizon, Vistara |
31.9B | 48.0% | - | 69.9% | - | 10.7% |
| BIIB Biogen |
Biotechnology
Multiple Sclerosis, Spinal |
26.1B | 64.5% | - | 42.0% | 16.2 | 4.22% |
| BNTX BioNTech SE |
Biotechnology
Cancer Immunotherapies |
25.1B | 14.3% | 1.0% | -31.1% | - | -32.8% |
| 22UA BioNTech SE |
Biotechnology
Cancer Vaccines, Immunotherapies |
23.2B | 11.0% | 1.0% | -34.9% | - | -40.4% |
| UTHR United Therapeutics |
Biotechnology
Treprostinil, Orenitram, Unituxin |
22.5B | 87.9% | - | 52.6% | 18.5 | 9.45% |
| RGC Regencell |
Biotechnology
TCM Formulations, Neurocognitive |
20.5B | 37.0% | - | 51.4% | - | -17.3% |
| INCY Incyte |
Biotechnology
JAKAFI, MONJUVI, PEMAZYRE |
19.9B | 89.1% | - | 61.8% | 17.2 | 25.2% |
| GMAB Genmab AS |
Biotechnology
Antibody Therapies, Oncological |
19.7B | 78.2% | - | 46.9% | 14.0 | 27.9% |
| RVMD Revolution |
Biotechnology
RAS Inhibitors, Companion |
15.4B | 28.3% | - | 75.7% | - | 135% |
| BIM Biomerieux |
Biotechnology
Chromogenic Media, Blood Culture |
15.1B | 78.1% | 60.0% | -9.15% | 34.7 | -11.5% |
| ROIV Roivant Sciences |
Biotechnology
Antibody, Small-Molecule, Inhaled |
15.1B | 31.9% | - | 82.8% | - | 70.9% |
| BBIO BridgeBio Pharma |
Biotechnology
ATTR-CM, Achondroplasia |
14.7B | 45.0% | - | 87.3% | - | 120% |
| SMMT Summit Therapeutics |
Biotechnology
Ivonescimab, Bispecific Antibody |
14.2B | 43.3% | - | 0.20% | - | -8.86% |
| NBIX Neurocrine |
Biotechnology
Movement, Endocrine, Psychiatric |
14.0B | 84.5% | - | 5.94% | 33.6 | -20.3% |
| MDGL Madrigal |
Biotechnology
Rezdiffra, MASH, Thyroid |
13.5B | 32.1% | - | 56.5% | - | 25.4% |
| ASND Ascendis Pharma AS |
Biotechnology
TransCon, Hormone, Parathyroid |
13.0B | 36.4% | - | 54.2% | - | 29.9% |
| IONS Ionis |
Biotechnology
RNA-Targeted, Neurological, Rare |
12.8B | 22.0% | 1.0% | 67.1% | - | 98.6% |
| ERF Eurofins |
Biotechnology
Testing, Laboratory, Diagnostics |
12.8B | 69.9% | 12.5% | 52.5% | 27.3 | 18.0% |
| EXEL Exelixis |
Biotechnology
Cancer, Medicines, Tablets |
12.4B | 91.7% | - | 67.9% | 18.3 | 1.07% |
| MRNA Moderna |
Biotechnology
Vaccines, Respiratory, Oncology |
12.1B | 22.6% | - | -2.18% | - | -32.9% |
| BMRN Biomarin |
Biotechnology
Enzyme Replacement, Growth |
11.8B | 84.2% | - | -39.1% | 22.3 | -27.7% |
| RNA Avidity Biosciences |
Biotechnology
Antibody-Oligonucleotide |
10.9B | 33.0% | - | 76.3% | - | 103% |
| ARWR Arrowhead |
Biotechnology
Plozasiran, Olpasiran, Fazirsiran |
9.37B | 49.3% | - | 68.3% | - | 189% |
| HALO Halozyme |
Biotechnology
Recombinant Enzyme, Subcutaneous |
8.83B | 89.3% | - | 48.9% | 15.4 | 13.5% |
| ABVX Abivax American |
Biotechnology
Obefazimod, Immunoregulatory |
8.19B | 40.9% | - | 79.1% | - | 1,382% |
| ABVX Abivax |
Biotechnology
Immunomodulator, Inflammatory |
8.13B | 31.9% | - | 78.9% | - | 1,165% |
| GRFS Grifols |
Biotechnology
Immunoglobulin, Albumin, Clotting |
7.65B | 65.2% | 2.30% | 17.0% | 13.8 | 8.01% |
| CYTK Cytokinetics |
Biotechnology
Cardiac Activator, Cardiac |
7.55B | 38.1% | - | 52.6% | - | 10.8% |
| NUVL Nuvalent |
Biotechnology
Ros1 Inhibitor, Alk Inhibitor |
7.33B | 30.8% | - | 69.7% | - | 13.4% |
| PRAX Praxis Precision |
Biotechnology
Ulixacaltamide, Vormatrigine |
7.16B | 33.3% | - | 58.5% | - | 278% |
| KRYS Krystal Biotech |
Biotechnology
Genetic Medicines, Dystrophic |
7.15B | 83.7% | - | 81.7% | 36.9 | 41.3% |
| RYTM Rhythm |
Biotechnology
Imcivree, Setmelanotide, Obesity |
7.01B | 42.2% | - | 45.7% | - | 48.7% |
| CDTX Cidara Therapeutics |
Biotechnology
Antifungal, Antiviral, Oncology |
6.95B | 23.5% | - | 66.6% | - | 665% |
| PTCT PTC Therapeutics |
Biotechnology
Translarna, Emflaza, Upstaza |
6.17B | 78.2% | - | 64.4% | 8.94 | 45.9% |
| PCVX Vaxcyte |
Biotechnology
Pneumococcal, Streptococcus |
6.04B | 30.0% | - | 12.6% | - | -53.1% |
| BLTE Belite Bio |
Biotechnology
Oral Therapy, Stargardt |
6.00B | 34.2% | - | 63.8% | - | 136% |
| KYMR Kymera Therapeutics |
Biotechnology
IRAK4, STAT6, TYK2, Protein |
5.82B | 31.2% | - | 66.8% | - | 61.9% |
| PTGX Protagonist |
Biotechnology
Peptide, Hematology, Inflammation |
5.46B | 64.0% | - | 61.0% | 132 | 81.1% |
| COGT Cogent Biosciences |
Biotechnology
Kinase Inhibitor, FGFR Inhibitor |
5.34B | 49.3% | - | 69.4% | - | 273% |
| IMVT Immunovant |
Biotechnology
Monoclonal Antibodies, Autoimmune |
5.22B | 29.4% | - | 29.8% | - | -8.36% |
| APGE Apogee |
Biotechnology
Monoclonal Antibody, Atopic |
5.16B | 36.3% | - | 84.5% | - | 57.1% |
| CRSP Crispr Therapeutics |
Biotechnology
Gene Editing, CAR-T |
5.12B | 32.2% | - | 30.2% | - | 12.1% |
| ALKS Alkermes |
Biotechnology
Schizophrenia, Bipolar, Alcohol |
4.85B | 89.2% | - | -9.36% | 14.3 | -12.7% |
| GPCR Structure |
Biotechnology
GSBR-1290, ACCG-2671, ANPA-0073 |
4.81B | 33.8% | - | 59.7% | - | 125% |
| TGTX TG Therapeutics |
Biotechnology
Briumvi, Ublituximab, Tg-1701 |
4.65B | 70.6% | - | -10.7% | 10.6 | -18.5% |
| CELC Celcuity |
Biotechnology
Cancer Test, Therapy Candidate |
4.62B | 28.6% | - | 68.3% | - | 646% |
| INDV Indivior Ordinary |
Biotechnology
Suboxone, Sublocade, Subutex, Opvee |
4.49B | 74.0% | 1.48% | 67.5% | 36.6 | 147% |
| ACAD ACADIA |
Biotechnology
Antipsychotic, Rett |
4.45B | 76.2% | - | 59.9% | 17.3 | 28.3% |
| CRNX Crinetics |
Biotechnology
Paltusotine, Atumelnant, CRN09682 |
4.43B | 26.1% | - | 39.9% | - | 8.45% |
| FOLD Amicus Therapeutics |
Biotechnology
Galafold, Pombiliti, Opfolda, Gene |
4.41B | 51.9% | - | 64.0% | - | 30.9% |
| ADMA ADMA Biologics |
Biotechnology
Immunoglobulin, Hepatitis |
4.27B | 84.3% | - | 8.49% | 20.8 | -20.1% |
| SRRK Scholar Rock |
Biotechnology
Monoclonal Antibodies, Inhibitor |
4.25B | 27.0% | - | 8.45% | - | -13.9% |
| MIRM Mirum |
Biotechnology
LIVMARLI, Cholbam, Chenodal |
4.22B | 47.3% | - | 68.6% | - | 73.2% |
| NAMS NewAmsterdam |
Biotechnology
Obicetrapib, Ezetimibe, CETP |
3.99B | 27.9% | - | 47.5% | - | 13.9% |
| GRAL GRAIL |
Biotechnology
Cancer Screening, Diagnostic Aid |
3.82B | 40.2% | - | 82.4% | - | 367% |
| LEGN Legend Biotech |
Biotechnology
CAR-T Therapy, Multiple Myeloma |
3.75B | 29.0% | - | -47.2% | - | -42.0% |
| LGND Ligand |
Biotechnology
Infectious, Oncology, Nephrology |
3.72B | 49.8% | 1.0% | 68.3% | 83.3 | 60.7% |
| ACLX Arcellx |
Biotechnology
Anitocabtagene Autoleucel |
3.72B | 38.9% | - | -12.0% | - | -20.7% |
| VKTX Viking Therapeutics |
Biotechnology
VK2809, VK2735, VK5211, VK0214 |
3.65B | 29.4% | - | 9.84% | - | -32.7% |
| ARQT Arcutis |
Biotechnology
Topical Cream, Topical Foam, JAK1 |
3.58B | 41.9% | - | 59.6% | - | 68.9% |
| TVTX Travere |
Biotechnology
Medication, Tablets, Enzyme |
3.54B | 27.6% | - | 49.9% | - | 58.0% |
| CNTA Centessa |
Biotechnology
OX2R Agonist, Neurological Drugs |
3.46B | 33.3% | - | 36.7% | - | 18.5% |
| XENE Xenon |
Biotechnology
Kv7 Opener, Phase 3, Epilepsy |
3.44B | 30.4% | - | 25.6% | - | -9.29% |
| VCYT Veracyte |
Biotechnology
Thyroid, Prostate, Bladder |
3.35B | 63.5% | - | 29.3% | 112 | -16.3% |
| CGON CG Oncology |
Biotechnology
Oncolytic Virus, Immunotherapy |
3.35B | 32.1% | - | 61.5% | - | 48.4% |
| VERA Vera Therapeutics |
Biotechnology
Atacicept, Mab, Dual-Inhibitor |
3.30B | 26.5% | 2.43% | 53.6% | - | 8.77% |
| APLS Apellis |
Biotechnology
Therapeutic, Complement |
3.18B | 76.1% | - | -23.2% | 69.8 | -17.8% |
| KNSA Kiniksa |
Biotechnology
ARCALYST, Vixarelimab, KPL-387 |
3.13B | 66.9% | - | 62.0% | 91.7 | 77.0% |
| NUVB Nuvation Bio |
Biotechnology
Taletrectinib, Safusidenib |
3.07B | 38.8% | - | 73.3% | - | 139% |
| DYN Dyne Therapeutics |
Biotechnology
Antisense Oligos, FORCE Platform |
3.05B | 31.5% | - | 2.30% | - | -7.44% |
| IDYA Ideaya Biosciences |
Biotechnology
Oncology, Kinase, Inhibitor, ADC |
3.03B | 23.2% | - | 81.8% | - | 28.6% |
| RCUS Arcus Biosciences |
Biotechnology
Cancer, Immunotherapy |
2.95B | 33.3% | - | 51.2% | - | 22.3% |
| VRDN Viridian |
Biotechnology
Monoclonal Antibody, Thyroid Eye |
2.93B | 34.7% | - | 56.2% | - | 44.2% |
| IRON Disc Medicine |
Biotechnology
Porphyria Drug, Anemia Drug |
2.92B | 35.5% | - | 30.6% | - | 9.03% |
| CPRX Catalyst |
Biotechnology
Firdapse, Fycompa, Ruzurgi, Agamree |
2.85B | 89.6% | - | 24.1% | 13.5 | -14.3% |
| MLYS Mineralys |
Biotechnology
Phase II Inhibitor, Oral |
2.83B | 30.5% | - | 36.5% | - | 179% |
| BEAM Beam Therapeutics |
Biotechnology
Base-Editing Therapeutics, Sickle |
2.81B | 28.1% | - | -8.70% | - | -13.7% |
| SYRE Spyre Therapeutics |
Biotechnology
Monoclonal Antibodies |
2.54B | 29.9% | - | 29.2% | - | 12.7% |
| DNLI Denali Therapeutics |
Biotechnology
RIPK1 Inhibitor, eIF2B Activator |
2.54B | 25.6% | - | -9.71% | - | -26.1% |
| SLNO Soleno Therapeutics |
Biotechnology
Diazoxide, Prader-Willi, Rare |
2.53B | 29.6% | - | -31.8% | - | -17.6% |
| EWTX Edgewise |
Biotechnology
EDG-5506, EDG-7500, Oral |
2.51B | 30.0% | - | 13.2% | - | -14.8% |
| SRPT Sarepta |
Biotechnology
RNA Therapeutics, Duchenne |
2.46B | 30.2% | - | -31.6% | - | -84.2% |
| IMNM Immunome |
Biotechnology
Gamma Secretase Inhibitor, ADC |
2.37B | 34.0% | - | 76.8% | - | 64.3% |
| RARE Ultragenyx |
Biotechnology
Biologic, Gene Therapy, Antibody |
2.28B | 36.8% | - | -37.2% | - | -55.8% |
| RXRX Recursion |
Biotechnology
Drug Discovery Platform |
2.19B | 33.3% | - | -46.7% | - | -44.0% |
| GLPG Galapagos |
Biotechnology
Medicine, Oncology, Immunology |
2.17B | 38.2% | - | 27.5% | - | 6.71% |
| GLPG Galapagos |
Biotechnology
CAR-T, Oncology, Immunology |
2.17B | 26.0% | - | 9.85% | - | -6.45% |
| TWST Twist Bioscience |
Biotechnology
Synthetic DNA, Gene Fragments |
2.13B | 36.4% | - | 12.2% | - | -33.0% |
| IBRX Immunitybio |
Biotechnology
Immunotherapy, Vaccine, Cytokine |
2.05B | 66.2% | - | -42.8% | - | -20.4% |
| OLMA Olema |
Biotechnology
Palazestrant, OP-3136 |
2.03B | 35.0% | - | 71.9% | - | 361% |
| AUPH Aurinia |
Biotechnology
Immunosuppressant, Lupus |
2.02B | 93.6% | - | 72.8% | 27.4 | 55.2% |
| ZYME Zymeworks Common |
Biotechnology
Zanidatamab, Bispecific Antibody |
2.02B | 30.8% | - | 57.4% | - | 44.9% |
| MESO Mesoblast |
Biotechnology
Stem-Cell Therapy, Inflammation |
1.94B | 36.5% | - | 20.6% | - | 2.34% |
| ZLAB Zai Lab |
Biotechnology
Oncology, Immunology, Neurology |
1.92B | 31.9% | - | -68.8% | - | -39.4% |
| ZBIO Zenas BioPharma |
Biotechnology
Obexelimab, ZB002, ZB004, ZB001 |
1.91B | 31.4% | - | 29.5% | 2.61 | 63.7% |
| NRIX Nurix Therapeutics |
Biotechnology
BTK Degrader, CBL-B Inhibitor |
1.87B | 35.8% | - | 15.7% | - | -12.5% |
| STOK Stoke Therapeutics |
Biotechnology
Antisense, Oligonucleotide |
1.86B | 73.5% | - | 66.0% | 47.9 | 202% |
| SION Sionna |
Biotechnology
Galicaftor, Navocaftor, SION-109 |
1.84B | 36.9% | - | 55.3% | - | 88.3% |
| SNDX Syndax |
Biotechnology
Menin Inhibitor, CSF-1R Antibody |
1.83B | 26.7% | - | 39.0% | - | 32.4% |
| DVAX Dynavax |
Biotechnology
Hepatitis Vaccine, Adjuvant |
1.81B | 37.2% | - | 34.2% | - | 0.86% |
| VCEL Vericel Ord |
Biotechnology
Cartilage, Skin, Burn, Autologous |
1.80B | 62.5% | - | 3.71% | 137 | -46.4% |
| CLDX Celldex |
Biotechnology
Antibody, Monoclonal, Bispecific |
1.79B | 31.5% | - | 11.9% | - | -7.05% |
| PHVS Pharvaris BV |
Biotechnology
Bradykinin, Antagonist |
1.72B | 24.4% | - | 66.9% | - | 20.2% |
| IMCR Immunocore Holdings |
Biotechnology
Immunotherapy, Oncology, Melanoma |
1.71B | 41.1% | - | 3.50% | - | -10.3% |
| KOD Kodiak Sciences |
Biotechnology
Anti-VEGF Biopolymer, Anti-Il6 |
1.71B | 47.2% | - | 86.3% | - | 175% |
| DNTH Dianthus |
Biotechnology
Monoclonal Antibody, C1s |
1.70B | 26.6% | - | 67.0% | - | 30.5% |
| BCRX BioCryst |
Biotechnology
Antiviral, Hae, Complement, Protein |
1.67B | 72.1% | - | -37.2% | - | -20.3% |
| AGIO Agios Pharm |
Biotechnology
Mitapivat, Tebapivat, AG-181 |
1.58B | 35.7% | - | -40.4% | - | -31.8% |
| MNKD MannKind |
Biotechnology
Inhaled Insulin, Insulin Delivery |
1.56B | 63.6% | - | 11.8% | 50.7 | -20.6% |
| TSHA Taysha Gene |
Biotechnology
Gene Therapy, Rett Syndrome, CLN1 |
1.51B | 34.2% | - | 67.6% | - | 134% |
| BHVN Biohaven |
Biotechnology
Troriluzole, Taldefgrobep |
1.50B | 32.5% | - | -63.0% | - | -75.0% |
| ARDX Ardelyx |
Biotechnology
IBS-C Therapy, Phosphate |
1.49B | 33.4% | - | 48.8% | - | 26.2% |
| MEDCL Medincell |
Biotechnology
Antipsychotic, Analgesic |
1.49B | 58.6% | - | 36.2% | - | 27.8% |
| ALVO Alvotech |
Biotechnology
Biosimilar, Autoimmune, Oncology |
1.47B | 37.4% | - | -67.9% | 20.6 | -71.6% |
| ERAS Erasca |
Biotechnology
Naporafenib, ERAS-007, ERAS-601 |
1.47B | 36.4% | - | 60.6% | - | 136% |
| QURE Uniqure |
Biotechnology
Gene Therapy, Hemophilia B |
1.46B | 38.4% | - | 27.0% | - | 51.1% |
| ATAI ATAI Life Sciences |
Biotechnology
Psychedelic, Serotonergic |
1.44B | 37.9% | - | 19.7% | - | 107% |
| BTX BlackRock |
Biotechnology
Tech, Private Equity, Mutual Fund |
1.44B | 34.0% | 85.7% | -4.02% | 56.1 | -15.1% |
| MNMD Mind Medicine |
Biotechnology
MM120, MM402, Trial, Anxiety |
1.43B | 32.4% | - | 69.0% | - | 65.1% |
| RLAY Relay Therapeutics |
Biotechnology
RLY-2608, RLY-4008, RLY-8161 |
1.42B | 35.3% | - | 37.6% | - | 48.4% |
| NNNN Anbio |
Biotechnology
Antigen Tests, Immunoassay |
1.41B | 68.2% | - | 48.7% | 535 | 429% |
| TYRA Tyra Biosciences |
Biotechnology
FGFR, Precision, Platform |
1.40B | 29.9% | - | 79.4% | - | 59.4% |
| CAPR Capricor |
Biotechnology
Deramiocel, Exosome Vaccine |
1.39B | 28.3% | - | 54.8% | - | 49.4% |
| MBX MBX Biosciences |
Biotechnology
Peptide Prodrug, GLP-1 Antagonist |
1.37B | 32.6% | - | 85.9% | 3.98 | 91.2% |
| PGEN Precigen |
Biotechnology
Gene Therapy, UltraCAR-T |
1.36B | 34.7% | - | 54.2% | - | 223% |
| ORKA Oruka Therapeutics |
Biotechnology
Monoclonal Antibody |
1.29B | 28.5% | 1.0% | 52.4% | - | 46.5% |
| UPB Upstream Bio |
Biotechnology
Clinical-Stage, Therapeutic |
1.26B | 38.1% | - | 88.3% | - | 79.5% |
| ANAB AnaptysBio |
Biotechnology
Rosnilimab, ANB032, ANB033 |
1.26B | 25.2% | - | 78.2% | - | 160% |
| IMTX Immatics |
Biotechnology
TCR Bispecifics, ACT Cell |
1.25B | 21.7% | - | 28.0% | - | 17.9% |
| PVLA Palvella |
Biotechnology
Rapamycin Gel, Rare Dermatology |
1.24B | 25.6% | - | 57.1% | - | 447% |
| TNGX Tango Therapeutics |
Biotechnology
PRMT5 Inhibitors, Brain-Penetrant |
1.19B | 34.2% | - | 78.2% | - | 232% |
| PHARM Pharming |
Biotechnology
Recombinant C1-Inhibitor |
1.19B | 66.8% | - | 59.8% | - | 46.4% |
| NVAX Novavax |
Biotechnology
Vaccine, Adjuvant, Nanoparticle |
1.16B | 39.8% | - | -19.9% | 3.35 | -35.5% |
| OCS Oculis Holding |
Biotechnology
OCS-01, OCS-02, OCS-05 |
1.15B | 25.4% | - | 43.5% | - | -9.83% |
| SVRA Savara |
Biotechnology
Inhaled Immunostimulant, Orphan |
1.15B | 22.4% | - | 77.8% | - | 72.8% |
| SPRY ARS |
Biotechnology
Epinephrine, Nasal Spray |
1.14B | 29.5% | - | 26.3% | - | -3.95% |
| CSTL Castle Biosciences |
Biotechnology
Melanoma, Squamous, Esophagus |
1.14B | 53.9% | - | 41.4% | - | 7.50% |
| SANA Sana Biotechnology |
Biotechnology
Islet Cell Therapy, CAR-T Cell |
1.12B | 35.3% | - | 47.7% | - | 2.99% |
| URGN UroGen Pharma |
Biotechnology
Jelmyto, UGN-102, UGN-103 |
1.10B | 48.5% | - | 45.3% | - | 71.5% |
| NANO Nanobiotix S.A |
Biotechnology
Nanoparticle Radiotherapy |
1.07B | 37.2% | - | 44.6% | - | 394% |
| NTLA Intellia |
Biotechnology
In-Vivo CRISPR, CAR-T, NK Cell |
1.07B | 33.3% | - | -32.1% | - | -15.9% |
| XNCR Xencor |
Biotechnology
Monoclonal Antibodies, Bispecific |
1.07B | 14.5% | - | -12.2% | - | -44.3% |
| CVAC CureVac |
Biotechnology
Mrna, Vaccines, Oncology |
1.05B | 26.6% | - | 2.55% | 6.96 | -8.20% |
| 5CV CureVac |
Biotechnology
Vaccines, Oncology, mRNA, Printer |
1.04B | 27.2% | - | -29.2% | 6.85 | -23.9% |
| ABCL Abcellera Biologics |
Biotechnology
Antibody, Metabolic, Autoimmune |
1.03B | 16.4% | - | 17.9% | - | 23.7% |
| GLUE Monte Rosa |
Biotechnology
MGD Pipeline, MRT-2359, MRT-6160 |
1.02B | 71.9% | - | 85.9% | 49.0 | 252% |
| CDNA CareDx |
Biotechnology
AlloSure, AlloMap, AlloSeq |
1.02B | 49.9% | - | 2.62% | 15.0 | -40.1% |
| OPK Opko Health |
Biotechnology
Diagnostics, Laboratory-Testing |
1.01B | 21.3% | - | -38.9% | - | -23.5% |
| BBOT BridgeBio Oncology |
Biotechnology
KRAS Inhibitor, HER2 Therapy |
1.01B | 47.6% | - | 49.8% | - | 19.5% |
| IOVA Iovance |
Biotechnology
Amtagvi, Lifileucel, Proleukin |
1.00B | 42.7% | - | -19.7% | - | -68.4% |
| NBTX Nanobiotix |
Biotechnology
Nanoparticle-Based Radiotherapy |
966M | 49.0% | - | 43.7% | - | 500% |
| MDXG MiMedx |
Biotechnology
Placental Allografts, Wound Care |
960M | 86.4% | - | -31.9% | 24.0 | -41.7% |
| DAWN Day One |
Biotechnology
Tovorafenib, DAY301, VRK1 Inhibitor |
957M | 31.5% | - | -12.7% | - | -37.4% |
| ALMS Alumis |
Biotechnology
TYK2 Inhibitor, CNS TYK2 |
935M | 50.9% | - | 61.8% | - | 131% |
| CMPX Compass |
Biotechnology
Trocimig, CTX-471, CTX-8371 |
920M | 32.6% | - | 63.1% | - | 150% |
| ABUS Arbutus Biopharma |
Biotechnology
RNAi Therapy, PD-L1 Inhibitor, HBV |
917M | 29.9% | - | 66.0% | - | 16.1% |
| BCAX Bicara |
Biotechnology
Ficerafusp Alfa, Bifunctional |
907M | 31.4% | - | 19.7% | 3.08 | 3.19% |
| ESPR Esperion |
Biotechnology
Bempedoic Acid, Ezetimibe |
880M | 55.3% | - | 39.2% | - | 37.1% |
| IVA Inventiva S.A |
Biotechnology
Lanifibranor, Odiparcil, Tgf-Beta |
874M | 46.2% | - | 30.6% | - | 58.2% |
| MLTX MoonLake |
Biotechnology
Sonelokimab, Nanobody, IL-17A |
847M | 28.4% | - | 5.11% | - | -67.0% |
| GERN Geron |
Biotechnology
Telomerase Inhibitor |
843M | 27.3% | - | -19.8% | - | -65.1% |
| DBVT DBV Technologies |
Biotechnology
Viaskin Peanut, Viaskin Milk |
835M | 38.3% | - | 54.6% | - | 183% |
| KURA Kura Oncology |
Biotechnology
Ziftomenib, Tipifarnib, KO-2806 |
831M | 56.2% | - | 5.98% | - | 6.27% |
| VIR Vir Biotechnology |
Biotechnology
Antibodies, Vaccines, T-Cell |
826M | 29.6% | - | -21.4% | - | -60.0% |
| RAPT RAPT Therapeutics |
Biotechnology
CCR4 Antagonist, Inflammation |
826M | 27.9% | - | 36.4% | - | 163% |
| GHRS GH Research |
Biotechnology
Mebufotenin, Depression |
821M | 25.8% | - | 43.7% | - | 44.8% |
| JANX Janux Therapeutics |
Biotechnology
JANX007, JANX008, TRACTr, TRACIr |
821M | 39.9% | - | -45.9% | - | -75.0% |
| AVBP ArriVent |
Biotechnology
Firmonertinib, ARR-217, ARR-002 |
810M | 30.3% | - | 1.13% | - | -31.8% |
| ORIC Oric |
Biotechnology
ORIC-114, ORIC-944, ORIC-533 |
797M | 34.7% | - | -11.7% | - | -4.98% |
| ANNX Annexon |
Biotechnology
Antibody, Fragment, Oral |
789M | 36.7% | - | 17.0% | - | -10.2% |
| KALV Kalvista |
Biotechnology
Plasma Kallikrein Inhibitor, Oral |
781M | 39.7% | - | 63.5% | - | 76.9% |
| RIGL Rigel |
Biotechnology
Kinase Inhibitor, Blood Disorder |
777M | 93.1% | - | 61.8% | 6.92 | 108% |
| VLA Valneva SE |
Biotechnology
Vaccines, Chikungunya, Lyme, Zika |
750M | 25.4% | - | 20.1% | - | 58.8% |
| ATXS Astria Therapeutics |
Biotechnology
Navenibart, STAR-0310, Monoclonal |
747M | 36.2% | - | 33.7% | - | 42.9% |
| PROK ProKidney |
Biotechnology
Cell Therapy, Autologous Renal |
728M | 42.9% | - | -26.7% | - | 19.4% |
| CTMX CytomX Therapeutics |
Biotechnology
Antibody-Drug Conjugate, T-Cell |
722M | 60.5% | - | 81.9% | 14.2 | 309% |
| REPL Replimune |
Biotechnology
Oncolytic Immunotherapy, RP1, RP2 |
698M | 32.7% | - | -49.6% | - | -40.0% |
| IRWD Ironwood |
Biotechnology
Linaclotide, Apraglutide, IW-3300 |
695M | 57.6% | - | -0.40% | 23.7 | -15.3% |
| LXEO Lexeo |
Biotechnology
Gene Therapy, Cardiomyopathy |
694M | 33.8% | - | 43.5% | - | 36.4% |
| RGNX Regenxbio |
Biotechnology
Gene Therapy, Retinal Diseases |
687M | 19.1% | - | 63.0% | - | 60.6% |
| EBS Emergent |
Biotechnology
Vaccines, Antitoxins |
686M | 51.9% | 1.0% | 24.0% | 9.45 | 8.43% |
| GYRE Gyre Therapeutics |
Biotechnology
Pirfenidone, Hydronidone, F573 |
671M | 61.8% | 1.0% | -13.2% | 174 | -38.8% |
| GOSS Gossamer Bio |
Biotechnology
Seralutinib, GB002 |
667M | 36.0% | - | 35.1% | - | 113% |
| PRME Prime Medicine |
Biotechnology
Gene Editing, Prime Editor |
637M | 40.6% | - | -13.1% | - | 10.8% |
| MGTX MeiraGTx Holdings |
Biotechnology
Gene Therapy, Ocular |
629M | 38.8% | - | 2.23% | - | -1.20% |
| KROS Keros Therapeutics |
Biotechnology
KER-050, KER-012, KER-065 |
620M | 74.6% | - | 33.9% | 13.1 | 9.01% |
| MYGN Myriad Genetics |
Biotechnology
Oncology Tests, Womens Health |
618M | 36.6% | 1.0% | -33.3% | - | -63.3% |
| DRUG Bright Minds |
Biotechnology
Serotonin Agonists, Epilepsy |
608M | 27.8% | - | 90.2% | - | 84.4% |
| CGEM Cullinan Oncology |
Biotechnology
Zipalertinib, CLN-978, CLN-619 |
598M | 31.4% | - | 15.4% | - | -19.5% |
| ENGN enGene Holdings |
Biotechnology
Bladder Cancer Therapy, Gene |
593M | 29.4% | - | 43.3% | - | -3.72% |